NIH-funded research Sbir 2 grant

Nebulized NO-releasing therapy for Pseudomonas infections in bronchiectasis

Official title: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients

Funded at Vast Therapeutics, INC. · NIH-11250047 · Data updated 2026-11-12

A new inhaled nitric oxide–releasing treatment is being tested to help people with bronchiectasis who have lung infections from Pseudomonas bacteria.

More Bronchiectasis research and trials

Quick facts

Grant typeSbir 2 grant
Study typeNIH-funded research
Funding institutionVast Therapeutics, INC.
NIH-funded
Lab location1 site (Morrisville, UNITED STATES)
Project startDecember 20, 2024
Project endNovember 30, 2026
Funding year2026
Award (this year)$988,594
NIH project number5R44AI184225-02
Project IDNIH-11250047 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are adults with bronchiectasis and a history of Pseudomonas aeruginosa infections.

Less likely to help

Patients without bronchiectasis or without Pseudomonas infections may not benefit from this approach.

What this research studies

Bronchiectasis can cause damaged airways and chronic lung infections, especially from Pseudomonas aeruginosa. This project explores a nitric oxide–releasing formulation delivered through the lungs to kill bacteria directly at the infection site. The study includes preclinical and early clinical development steps to understand how the drug behaves in the body and how it reaches the lungs. If successful, it could lead to more effective infection control with less harm to patients’ lungs.

Why it matters

Potential benefit: If successful, patients could experience better control of lung infections and slower decline in lung function.

How similar studies have gone: Early non-human and human data suggest inhaled NO–releasing therapies can reduce lung bacteria and inflammation, but clinical effectiveness in bronchiectasis is still being established.

Where this research is happening

  • Vast Therapeutics, INC.
    Morrisville, United States
    Active

Researchers

  • Principal investigator: Stasko, Nathan Allan — Vast Therapeutics, INC.
  • Study coordinator: Stasko, Nathan Allan

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.